The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation
Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor. Effective interventions to reduce DSAs are still needed, and the cost of the current...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Cell Transplantation |
| Online Access: | https://doi.org/10.1177/09636897241303292 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583169656750080 |
|---|---|
| author | Xiaoping Li Yu Li Dingsong Zhang Xiaozhuang Hu Lin Liu Zhongtao Yuan Shiqi Li Yancheng Dong Yingnian Chen Sanbin Wang |
| author_facet | Xiaoping Li Yu Li Dingsong Zhang Xiaozhuang Hu Lin Liu Zhongtao Yuan Shiqi Li Yancheng Dong Yingnian Chen Sanbin Wang |
| author_sort | Xiaoping Li |
| collection | DOAJ |
| description | Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor. Effective interventions to reduce DSAs are still needed, and the cost of the current therapies is relatively high. In this study, we retrospectively analyzed the data of 11 DSA-positive patients who received haplo-HSCT at our center and evaluated the therapeutic efficacy of the combination of intravenous immunoglobulin (IVIG), dexamethasone and high dose of transfused mononuclear cells (MNCs) for DSA desensitization. The kinetics of DSAs at different times and the engraftment and transplantation outcomes were also observed. We found that all patients had successful donor-cell engraftment and that no patient developed poor graft function. The median engraftment times of neutrophils and platelets were 14 days (range, 11–24 days) and 13 days (range, 11–123 days), respectively. The DSA levels of all patients became negative or dropped under 2000 within 22 days after HSCT. A total of 36.4% of patients developed grade II–IV acute graft-versus-host disease (aGVHD), and 9.1% of patients died of severe gastrointestinal aGVHD. Of the 7 surviving patients, four were diagnosed with chronic GVHD. After a median follow-up of 28.9 months (2.0–52.1 months), four patients died: of relapse (two), aGVHD (one), and multiple-organ failure (one). The 2-year OS, DFS, and NRM were 63.6%, 45.4%, and 18.2%, respectively. Combination therapy with IVIG, dexamethasone, and a high dose of MNCs transfusion, a simple and efficient procedure, was safe and effective for DSA desensitization and peripheral blood stem cell (PBSC) engraftment. |
| format | Article |
| id | doaj-art-78acbdb3309a4fc79759a75b4d14a2d1 |
| institution | Kabale University |
| issn | 1555-3892 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cell Transplantation |
| spelling | doaj-art-78acbdb3309a4fc79759a75b4d14a2d12025-01-29T00:03:34ZengSAGE PublishingCell Transplantation1555-38922025-01-013410.1177/09636897241303292The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell TransplantationXiaoping Li0Yu Li1Dingsong Zhang2Xiaozhuang Hu3Lin Liu4Zhongtao Yuan5Shiqi Li6Yancheng Dong7Yingnian Chen8Sanbin Wang9Department of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, ChinaDepartment of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, ChinaDepartment of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, ChinaShanghai Tissuebank Biotechnology Co., Ltd, Shanghai, ChinaDepartment of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, ChinaDepartment of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, ChinaDepartment of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, ChinaDepartment of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, ChinaDepartment of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, ChinaDepartment of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, ChinaDonor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor. Effective interventions to reduce DSAs are still needed, and the cost of the current therapies is relatively high. In this study, we retrospectively analyzed the data of 11 DSA-positive patients who received haplo-HSCT at our center and evaluated the therapeutic efficacy of the combination of intravenous immunoglobulin (IVIG), dexamethasone and high dose of transfused mononuclear cells (MNCs) for DSA desensitization. The kinetics of DSAs at different times and the engraftment and transplantation outcomes were also observed. We found that all patients had successful donor-cell engraftment and that no patient developed poor graft function. The median engraftment times of neutrophils and platelets were 14 days (range, 11–24 days) and 13 days (range, 11–123 days), respectively. The DSA levels of all patients became negative or dropped under 2000 within 22 days after HSCT. A total of 36.4% of patients developed grade II–IV acute graft-versus-host disease (aGVHD), and 9.1% of patients died of severe gastrointestinal aGVHD. Of the 7 surviving patients, four were diagnosed with chronic GVHD. After a median follow-up of 28.9 months (2.0–52.1 months), four patients died: of relapse (two), aGVHD (one), and multiple-organ failure (one). The 2-year OS, DFS, and NRM were 63.6%, 45.4%, and 18.2%, respectively. Combination therapy with IVIG, dexamethasone, and a high dose of MNCs transfusion, a simple and efficient procedure, was safe and effective for DSA desensitization and peripheral blood stem cell (PBSC) engraftment.https://doi.org/10.1177/09636897241303292 |
| spellingShingle | Xiaoping Li Yu Li Dingsong Zhang Xiaozhuang Hu Lin Liu Zhongtao Yuan Shiqi Li Yancheng Dong Yingnian Chen Sanbin Wang The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation Cell Transplantation |
| title | The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation |
| title_full | The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation |
| title_fullStr | The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation |
| title_full_unstemmed | The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation |
| title_short | The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation |
| title_sort | combination of intravenous immunoglobulin dexamethasone and a high dose of mononuclear cells transfusion an effective strategy for decreasing donor specific antibodies during haploidentical hematopoietic stem cell transplantation |
| url | https://doi.org/10.1177/09636897241303292 |
| work_keys_str_mv | AT xiaopingli thecombinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT yuli thecombinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT dingsongzhang thecombinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT xiaozhuanghu thecombinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT linliu thecombinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT zhongtaoyuan thecombinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT shiqili thecombinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT yanchengdong thecombinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT yingnianchen thecombinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT sanbinwang thecombinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT xiaopingli combinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT yuli combinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT dingsongzhang combinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT xiaozhuanghu combinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT linliu combinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT zhongtaoyuan combinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT shiqili combinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT yanchengdong combinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT yingnianchen combinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation AT sanbinwang combinationofintravenousimmunoglobulindexamethasoneandahighdoseofmononuclearcellstransfusionaneffectivestrategyfordecreasingdonorspecificantibodiesduringhaploidenticalhematopoieticstemcelltransplantation |